Pien Huang Pien Huang is a health reporter on the Science desk. She was NPR's first Reflect America Fellow, working with shows, desks and podcasts to bring more diverse voices to air and online.
Pien Huang
Stories By

Pien Huang

Wanyu Zhang/NPR
Pien Huang
Wanyu Zhang/NPR

Pien Huang

Reporter, Science Desk

Pien Huang is a health reporter on the Science desk. She was NPR's first Reflect America Fellow, working with shows, desks and podcasts to bring more diverse voices to air and online.

She's a former producer for WBUR/NPR's On Point and was a 2018 Environmental Reporting Fellow with The GroundTruth Project at WCAI in Cape Cod, covering the human impact on climate change. As a freelance audio and digital reporter, Huang's stories on the environment, arts and culture have been featured on NPR, the BBC and PRI's The World.

Huang's experiences span categories and continents. She was executive producer of Data Made to Matter, a podcast from the MIT Sloan School of Management, and was also an adjunct instructor in podcasting and audio journalism at Northeastern University. She worked as a project manager for public artist Ralph Helmick to help plan and execute The Founder's Memorial in Abu Dhabi and with Stoltze Design to tell visual stories through graphic design. Huang has traveled with scientists looking for signs of environmental change in Cameroon's frogs, in Panama's plants and in the ocean water off the ice edge of Antarctica. She has a degree in environmental science and public policy from Harvard.

Story Archive

The FDA is restricting the use of 2 drugs first authorized to treat COVID

  • Download
  • <iframe src="https://www.npr.org/player/embed/1075717086/1075717087" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">

Evusheld is a treatment authorized for prevention of COVID-19 in people who are seriously immunocompromised or who have had serious adverse reactions to COVID-19 vaccines. Peter Bostrom/AstraZeneca hide caption

toggle caption
Peter Bostrom/AstraZeneca

A drug that helps immunocompromised people fight COVID is in short supply

  • Download
  • <iframe src="https://www.npr.org/player/embed/1075488969/1075488970" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

President Biden speaks about the government's COVID-19 response on Thursday. Experts say his administration's efforts have yielded mixed results in the first year Biden's been in office. Andrew Harnik/AP hide caption

toggle caption
Andrew Harnik/AP

A year in, experts assess Biden's hits and misses on handling the pandemic

  • Download
  • <iframe src="https://www.npr.org/player/embed/1073292913/1073881798" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Advisers to the CDC say kids as young as 12 should get COVID booster shots

  • Download
  • <iframe src="https://www.npr.org/player/embed/1070700684/1070700685" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

People wait in line for a coronavirus test in Los Angeles on Tuesday. California is starting to feel the full wrath of the omicron variant. Hospitalizations have jumped nearly 50% since Christmas and models show that in a month, the state could have 22,000 people in hospitals, which was the peak during last winter's epic surge. Jae C. Hong/AP hide caption

toggle caption
Jae C. Hong/AP

People form a large crowd as they attempt to receive COVID-19 testing kits from city workers distributing the kits along Flatbush Avenue on December 24, 2021 in the Brooklyn borough of New York City. The city is handing out thousands of the kits, which include two tests per box, in order to lesson the surge of people in long lines at testing sites. Spencer Platt/Getty Images hide caption

toggle caption
Spencer Platt/Getty Images

The CDC shortens COVID isolation times for people who don't show symptoms

  • Download
  • <iframe src="https://www.npr.org/player/embed/1068430139/1068430140" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

CDC advisers recommend limiting the use of the J&J vaccine due to rare blood clots

  • Download
  • <iframe src="https://www.npr.org/player/embed/1064951618/1064951619" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Pfizer has announced new results for a pill that fights COVID-19

  • Download
  • <iframe src="https://www.npr.org/player/embed/1064011307/1064011308" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Molnupiravir, an antiviral drug to treat mild to moderate COVID-19, is under consideration by the FDA for possible authorization. Merck hide caption

toggle caption
Merck

The U.S. is one of 2 dozen nations that have confirmed cases of the omicron variant

  • Download
  • <iframe src="https://www.npr.org/player/embed/1060773346/1060773347" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Molnupiravir, an antiviral drug to treat mild to moderate COVID-19, is under consideration by the FDA for possible authorization. Merck hide caption

toggle caption
Merck

New antiviral drugs are coming for COVID. Here's what you need to know

  • Download
  • <iframe src="https://www.npr.org/player/embed/1059926089/1060212486" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

What the U.S. can learn from China's response to COVID infections

  • Download
  • <iframe src="https://www.npr.org/player/embed/1053647178/1053647179" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript